Eurozone private sector credit growth is reaching multi year highs, which indicates that households and businesses are still willing to borrow and invest. That kind of lending backdrop can support companies with healthy balance sheets and room to grow earnings. The Healthy high growth potential screener filters for exactly that type of stock. This article walks through three of the strongest candidates from that list.

The stocks highlighted below are just a starting sample, as the full screen has surfaced 1,559 more companies with similarly compelling growth and balance sheet stories that are not covered here. If you want to identify and analyze your own highest conviction ideas from this universe, head straight to the Healthy high growth potential screener.

Amylyx Pharmaceuticals (AMLX)

Overview: Amylyx Pharmaceuticals is a clinical stage biotech company developing treatments for neurodegenerative diseases and rare endocrine conditions, with late stage drug candidates such as avexitide for post bariatric hypoglycemia and AMX0035 for disorders like ALS and Wolfram syndrome. These programs support its inclusion in the Healthy high growth potential screener.

Market Cap: $4.7b

Amylyx Pharmaceuticals may warrant attention if you are interested in early stage growth stories where a single clinical success could significantly affect the earnings profile. Positive Phase 3 LUCIDITY data for avexitide in post bariatric hypoglycemia and plans to file an NDA with the FDA by the end of 2026 provide a clearer path toward the company’s first potential revenue line. A broader GLP 1 antagonist and neurodegeneration pipeline adds additional avenues for potential value creation. At the same time, Amylyx currently has no commercial revenue, continues to report losses and has relied on equity financing, which exposes investors to trial, regulatory and dilution risks. The balance between these risks and the potential PBH opportunity is the key point to consider.

Amylyx Pharmaceuticals sits at the junction of high stakes trial results and a potential first revenue stream, yet the full risk reward picture is easy to miss. Get the context from the 2 key rewards and 4 important warning signs (3 are major!)

Oracle (ORCL)

Overview: Oracle is a global enterprise software and cloud company that runs critical databases and business applications for large organisations. Its Oracle Cloud SaaS suite, including Fusion Cloud ERP, EPM, SCM, HCM and NetSuite, is now a key earnings driver as customers shift to subscription based cloud services. Alongside this cloud and software focus, Oracle still sells on premise licenses, hardware and consulting services, which keeps its business diversified beyond pure SaaS.

Operations: Oracle generates most of its revenue from Cloud and software at about US$58.5b, with smaller contributions from Services at roughly US$5.7b and Hardware at about US$3.1b.

Market Cap: US$417.0b

Oracle attracts interest if you want exposure to cloud and AI infrastructure backed by a very large backlog of contracted revenue, while still getting the stability of a long established enterprise software company. The Oracle Cloud SaaS suite and broader cloud stack support the Healthy high growth potential theme through current earnings and revenue forecasts, yet the stock trades on a P/E that is below many software peers. At the same time, heavy data center and AI investment funded by sizable debt and constrained near term free cash flow creates balance sheet and execution risk. The tension between this growth runway and the funding load is what makes Oracle a company some investors examine closely.

Oracle’s cloud and AI push may be masking what really matters in the numbers. Before you assume the story is straightforward, read the full 4 key rewards and 3 important warning signs (1 is major!)

Palantir Technologies (PLTR)

Overview: Palantir Technologies builds software platforms like Gotham and Foundry that help government and commercial customers turn large, complex data sets into real time intelligence and operational decisions, with the Palantir Artificial Intelligence Platform and Apollo tools linking that data engine directly to scalable AI and automation use cases. This combination of data infrastructure and AI deployment is the company’s clearest tie to healthy, high growth potential, even if not every dollar of revenue is yet driven by Foundry and related AI products.

Operations: Palantir generates roughly US$2.95b of revenue from Commercial customers and about US$3.21b from Government customers.

Market Cap: US$426.4b

Palantir Technologies often catches investor attention because its Foundry and AI platforms aim to be the operating system for data driven decisions across both government and commercial clients, and recent contracts like the Maven Smart System nearing US$1b in annual recurring revenue suggest that AI focused workloads are gaining traction. Earnings and revenue growth forecasts in the low 30% range, expanding profit margins and a strong record of large, multi year contracts reflect expectations for earnings power if adoption stays on track. The trade off is a rich valuation and funding structure that relies on external capital, which could be pressured if growth cools. For investors who can tolerate volatility, that combination of rapid growth, AI leverage and premium pricing is the key set of factors to consider.

Palantir’s accelerating AI contracts, together with its twin government and commercial engines, suggest a broader earnings story that many investors may be underestimating. Get the full picture from the analyst forecasts for Palantir Technologies

Seeking Fresh Alternatives Before They Fly?

Some stocks gain momentum quietly, then move fast once the crowd catches on. Scan these fresh ideas while they still appear under the radar and consider them before broader attention builds.

• Identify companies with strong balance sheets before they gain wider attention by running the list of solid balance sheet and fundamentals (51 results), which may help highlight under followed strength.
• Track potential income workhorses offering high yields by reviewing the curated 11 dividend fortresses before any changes in prices affect the yields.
• Explore early movers in AI infrastructure that may support future data demand by reviewing the focused 55 AI infrastructure stocks while the narrative is still developing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.